{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.3","upperLimit":"8.6","value":"4.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"The observed length of life from entry into the study to death or the date of last contact","dispersionType":"95% Confidence Interval","groups":[{"description":"Gleevec™ 600 mg QD po continuously (a cycle will be defined as 28 days). If first cycle of Gleevec™ at 600 mg QD is tolerated without any significant toxicity, the dose can be escalated to 400 mg BID po Q 12 hours until disease progression or adverse effects prohibit further therapy.","id":"OG000","title":"Gleevec"}],"paramType":"MEDIAN","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"From study entry to death or last contact, up to 5 years.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}